We are studying a new treatment called LY3962673 for people with advanced solid tumors. The goal is to understand its safety and how well it works compared to existing options.
Health conditions and diseases that the clinical trial is designed to study and treat.
KRAS G12D-mutant solid tumors are a type of cancer characterized by a specific mutation in the KRAS gene, which can affect treatment options and prognosis. These tumors can occur in various organs and are part of a larger group known as solid tumors.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
